a Department of Pharmaceutical Chemistry, College of Pharmacy , King Saud University , Riyadh , Saudi Arabia.
b Department of Pharmaceutical Chemistry, Drug Exploration and Development Chair (DEDC), College of Pharmacy , King Saud University , Riyadh , Saudi Arabia.
J Enzyme Inhib Med Chem. 2018 Dec;33(1):978-988. doi: 10.1080/14756366.2018.1474212.
Dihydropyrimidinone derivatives containing piperidine moiety were synthesised in a good yield. All the compounds were confirmed by elemental analysis and spectral data. Anti-ulcer activity of novel dihydropyrimidinone-piperidine hybrids (1-18) was evaluated. Among them, four compounds (3, 8, 11 and 15) were found to be most active in 80% ethanol-induced ulcer experimental animal model. All the potent compounds were further evaluated for anti-ulcer activity by different in vivo anti-ulcer models to study the effect of compounds on anti-secretory and cytoprotective activities. All the active compounds inhibited the formation of gastric ulcers and increased the formation of gastric mucin secretion. Compound 15 was found to be the most potent compound of the series as anti-ulcer agent. Additional experimental studies on lead compound 15 will result in a new class of orally active molecule for anti-ulcer activity.
含有哌啶部分的二氢嘧啶酮衍生物以良好的收率合成。所有化合物均通过元素分析和光谱数据得到证实。新型二氢嘧啶酮-哌啶杂合化合物(1-18)的抗溃疡活性进行了评价。其中,有 4 种化合物(3、8、11 和 15)在 80%乙醇诱导的溃疡实验动物模型中表现出最强的活性。所有有效化合物均通过不同的体内抗溃疡模型进一步评估抗溃疡活性,以研究化合物对抗分泌和细胞保护活性的影响。所有活性化合物均抑制了胃溃疡的形成,并增加了胃粘液分泌的形成。化合物 15 被发现是该系列中作为抗溃疡剂最有效的化合物。对先导化合物 15 的进一步实验研究将产生一类新的口服活性分子,用于抗溃疡活性。